Top

Published in:

01-02-2018

The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma

Authors: Randy Yeh, Laurent Dercle, Ishan Garg, Zhen Jane Wang, David M. Hough, Ajit H. Goenka

Published in: Abdominal Radiology | Issue 2/2018

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a difficult disease to treat and continues to portend a poor prognosis, as most patients are unresectable at diagnosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT (PET/CT) has been a cornerstone in oncological imaging of different cancers; however, the role of PET/CT in PDAC is continually evolving and currently not well established. Studies have shown the potential of PET/CT in guiding the management of patients with PDAC, with possible added benefit over anatomic imaging with CT or MRI in certain scenarios. PET/CT may be useful in diagnosis, initial staging, treatment response assessment, differentiation of recurrent tumor from post-treatment fibrosis, and radiotherapy planning. Additionally, PET/CT may be a cost-effective modality due to upstaging of patients originally deemed as surgical candidates. Recently, the advent of simultaneous PET/MRI represents an exciting advancement in hybrid functional imaging with potential applications in the imaging of PDAC. The advantages of PET/MRI include simultaneous acquisition to improve registration of fusion images, lower radiation dose, superior soft tissue contrast, and availability of multiparametric imaging. Studies are underway to evaluate the utility of PET/MRI in PDAC, including in initial staging and treatment response assessment and to determine the subgroup of patients that will benefit from PET/MRI. Further studies are warranted in both PET/CR and PET/MRI to better understand the role of these modalities in PDAC.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Pakzad F, Groves AM, Ell PJ (2006) The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36(3):248–256. https://doi.org/10.1053/j.semnuclmed.2006.03.005 CrossRefPubMed

Yeh R, Steinman J, Luk L, Kluger MD, Hecht EM (2017) Imaging of pancreatic cancer: what the surgeon wants to know. Clin Imaging 42:203–217. https://doi.org/10.1016/j.clinimag.2016.10.002 CrossRefPubMed

Cascinu S, Falconi M, Valentini V, Jelic S, Group EGW (2010) Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v55–58. https://doi.org/10.1093/annonc/mdq165 CrossRefPubMed

Seufferlein T, Bachet JB, Van Cutsem E, Rougier P, Group EGW (2012) Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii33–40. https://doi.org/10.1093/annonc/mds224 CrossRefPubMed

Hillner BE, Siegel BA, Shields AF, et al. (2008) Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 49(12):1928–1935. https://doi.org/10.2967/jnumed.108.056713 CrossRefPubMed

Halbrook CJ, Lyssiotis CA (2017) Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell 31(1):5–19. https://doi.org/10.1016/j.ccell.2016.12.006 CrossRefPubMed

Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033. https://doi.org/10.1126/science.1160809 CrossRefPubMedPubMedCentral

Zimny M, Bares R, Fass J, et al. (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24(6):678–682PubMed

10.

Dibble EH, Karantanis D, Mercier G, et al. (2012) PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol 199(5):952–967. https://doi.org/10.2214/AJR.11.8182 CrossRefPubMed

11.

Best LM, Rawji V, Pereira SP, Davidson BR, Gurusamy KS (2017) Imaging modalities for characterising focal pancreatic lesions. Cochrane Database Syst Rev 4:CD010213. https://doi.org/10.1002/14651858.CD010213.pub2 PubMed

12.

Murakami K (2011) FDG-PET for hepatobiliary and pancreatic cancer: advances and current limitations. World J Clin Oncol 2(5):229–236. https://doi.org/10.5306/wjco.v2.i5.229 CrossRefPubMedPubMedCentral

13.

Delbeke D, Rose DM, Chapman WC, et al. (1999) Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 40(11):1784–1791PubMed

14.

Kauhanen SP, Komar G, Seppanen MP, et al. (2009) A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 250(6):957–963. https://doi.org/10.1097/SLA.0b013e3181b2fafa CrossRefPubMed

15.

Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD (1999) 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 229 (5):729–737; discussion 737–728

16.

Stollfuss JC, Glatting G, Friess H, et al. (1995) 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 195(2):339–344. https://doi.org/10.1148/radiology.195.2.7724750 CrossRefPubMed

17.

Evan GI, Hah N, Littlewood TD, et al. (2017) Re-engineering the pancreas tumor microenvironment: A “Regenerative Program” Hacked. Clin Cancer Res 23(7):1647–1655. https://doi.org/10.1158/1078-0432.CCR-16-3275 CrossRefPubMedPubMedCentral

18.

Ozaki Y, Oguchi K, Hamano H, et al. (2008) Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol 43(2):144–151. https://doi.org/10.1007/s00535-007-2132-y CrossRefPubMed

19.

Lee TY, Kim MH, Park DH, et al. (2009) Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol 193(2):343–348. https://doi.org/10.2214/AJR.08.2297 CrossRefPubMed

20.

Lyall A, Vargas HA, Carvajal RD, Ulaner G (2012) Ipilimumab-induced colitis on FDG PET/CT. Clin Nucl Med 37(6):629–630. https://doi.org/10.1097/RLU.0b013e318248549a CrossRefPubMed

21.

Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19(1):82–92. https://doi.org/10.1007/s11102-015-0671-4 CrossRefPubMed

22.

Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48(6):932–945. https://doi.org/10.2967/jnumed.106.035774 CrossRefPubMed

23.

Soriano A, Castells A, Ayuso C, et al. (2004) Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 99(3):492–501. https://doi.org/10.1111/j.1572-0241.2004.04087.x CrossRefPubMed

24.

Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y (2013) FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol 19(29):4808–4817. https://doi.org/10.3748/wjg.v19.i29.4808 CrossRefPubMedPubMedCentral

25.

Barina AR, Bashir MR, Howard BA, et al. (2016) Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol (NY) 41(2):207–214. https://doi.org/10.1007/s00261-015-0560-3 CrossRef

26.

Wakabayashi H (2008) Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 14(1):64. https://doi.org/10.3748/wjg.14.64 CrossRefPubMedPubMedCentral

27.

Jain RK, Lee JJ, Ng C, et al. (2012) Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 30(21):2684–2690CrossRefPubMedPubMedCentral

28.

Sen N, Falk S, Abrams RA (2014) Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer. Clin Oncol (R Coll Radiol) 26(9):551–559. https://doi.org/10.1016/j.clon.2014.06.003 CrossRef

29.

Topkan E, Yavuz AA, Aydin M, et al. (2008) Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J Exp Clin Cancer Res 27:41. https://doi.org/10.1186/1756-9966-27-41 CrossRefPubMedPubMedCentral

30.

Yoshioka M, Sato T, Furuya T, et al. (2004) Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. J Gastroenterol 39(1):50–55. https://doi.org/10.1007/s00535-003-1244-2 CrossRefPubMed

31.

Heinrich S, Schafer M, Weber A, et al. (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248(6):1014–1022. https://doi.org/10.1097/SLA.0b013e318190a6da CrossRefPubMed

32.

Choi M, Heilbrun LK, Venkatramanamoorthy R, et al. (2010) Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol 33(3):257–261. https://doi.org/10.1097/COC.0b013e3181a76a0b PubMed

33.

Sperti C, Pasquali C, Bissoli S, et al. (2010) Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg 14(1):131–140. https://doi.org/10.1007/s11605-009-1010-8 CrossRefPubMed

34.

Cameron K, Golan S, Simpson W, et al. (2011) Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging 36(4):463–471. https://doi.org/10.1007/s00261-011-9729-6 CrossRefPubMed

35.

Toesca DA, Pollom EL, Poullos PD, et al. (2017) Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. Pract Radiat Oncol 7(2):120–125. https://doi.org/10.1016/j.prro.2016.09.002 CrossRefPubMed

36.

Ruf J, Lopez Hanninen E, Oettle H, et al. (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5(2–3):266–272. https://doi.org/10.1159/000085281 CrossRefPubMed

37.

Yamamoto T, Sugiura T, Mizuno T, et al. (2015) Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma. Ann Surg Oncol 22(2):677–684. https://doi.org/10.1245/s10434-014-4046-2 CrossRefPubMed

38.

Strobel K, Heinrich S, Bhure U, et al. (2008) Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 49(9):1408–1413. https://doi.org/10.2967/jnumed.108.051466 CrossRefPubMed

39.

Buchs NC, Buhler L, Bucher P, et al. (2011) Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study. J Gastroenterol Hepatol 26(4):657–662. https://doi.org/10.1111/j.1440-1746.2010.06525.x CrossRefPubMed

40.

Ford EC, Herman J, Yorke E, Wahl RL (2009) 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med 50(10):1655–1665. https://doi.org/10.2967/jnumed.108.055780 CrossRefPubMedPubMedCentral

41.

Li XX, Liu NB, Zhu L, et al. (2015) Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer. Br J Radiol 88(1051):20140590. https://doi.org/10.1259/bjr.20140590 CrossRefPubMedPubMedCentral

42.

Heinrich S, Goerres GW, Schafer M, et al. (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242(2):235–243CrossRefPubMedPubMedCentral

43.

Kamisawa T, Takum K, Anjiki H, et al. (2010) FDG-PET/CT findings of autoimmune pancreatitis. Hepato-gastroenterology 57(99–100):447–450PubMed

44.

Kato K, Nihashi T, Ikeda M, et al. (2013) Limited efficacy of 18F-FDG PET/CT for differentiation between metastasis-free pancreatic cancer and mass-forming pancreatitis. Clin Nucl Med 38(6):417. https://doi.org/10.1097/rlu.0b013e3182817d9d CrossRefPubMed

45.

Matsumoto I, Shirakawa S, Shinzeki M, et al. (2013) 18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 11(6):712–718. https://doi.org/10.1016/j.cgh.2012.12.033 CrossRefPubMed

46.

Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CHJ (2014) Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol (EJSO) 40(7):794–804. https://doi.org/10.1016/j.ejso.2014.03.016 CrossRef

47.

Attenberger U, Catana C, Chandarana H, et al. (2015) Whole-body FDG PET-MR oncologic imaging: pitfalls in clinical interpretation related to inaccurate MR-based attenuation correction. Abdom Imaging 40(6):1374–1386. https://doi.org/10.1007/s00261-015-0455-3 CrossRefPubMed

48.

Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA (2012) State-of-the-Art PET/CT of the pancreas: current role and emerging indications. Radiographics 32(4):1133–1158. https://doi.org/10.1148/rg.324115143 CrossRefPubMed

49.

Katz MHG, Fleming JB, Bhosale P, et al. (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749–5756. https://doi.org/10.1002/cncr.27636 CrossRefPubMed

50.

Lee D, Kim S, Im S-A, et al. (2015) Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. Eur Radiol 26(8):2771–2778. https://doi.org/10.1007/s00330-015-4105-5 CrossRefPubMed

51.

Broski Johnson GB, Goenka AH (2017) Gastrointestinal: Multiparametric hybrid 18-FDG PET/MRI evaluation of gastric adenocarcinoma. J Gastroenterol Hepatol 32(6):1132–1132. https://doi.org/10.1111/jgh.13631 CrossRefPubMed

52.

Kittaka H, Takahashi H, Ohigashi H, et al. (2013) Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J Surg 37(1):169–178. https://doi.org/10.1007/s00268-012-1775-x CrossRefPubMed

53.

Cuneo KC, Chenevert TL, Ben-Josef E, et al. (2014) A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol 7(5):644–649. https://doi.org/10.1016/j.tranon.2014.07.005 CrossRefPubMedPubMedCentral

54.

Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRefPubMedPubMedCentral

55.

Raman SP, Chen Y, Fishman EK (2015) Cross-sectional imaging and the role of positron emission tomography in pancreatic cancer evaluation. Semin Oncol 42(1):40–58. https://doi.org/10.1053/j.seminoncol.2014.12.005 CrossRefPubMed

56.

Wang X-Y, Yang F, Jin C, Fu D-L (2014) Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol 20(42):15580–15589. https://doi.org/10.3748/wjg.v20.i42.15580 CrossRefPubMedPubMedCentral

57.

58.

Liu RC, Traverso LW (2005) Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 19(5):638–642. https://doi.org/10.1007/s00464-004-8165-x CrossRefPubMed

59.

Izuishi K, Yamamoto Y, Sano T, et al. (2010) Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 14(7):1151–1158. https://doi.org/10.1007/s11605-010-1207-x CrossRefPubMed

60.

Lytras D, Connor S, Bosonnet L, et al. (2005) Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 22(1–2):55–62. https://doi.org/10.1159/000085347 CrossRefPubMed

61.

Bang S, Chung H, Park S, et al. (2006) The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40(10):923. https://doi.org/10.1097/01.mcg.0000225672.68852.05 CrossRefPubMed

62.

Farma JM, Santillan AA, Melis M, et al. (2008) PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 15(9):2465–2471. https://doi.org/10.1245/s10434-008-9992-0 CrossRefPubMed

63.

64.

Ruf J, Hänninen LE, Oettle H, et al. (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5(2–3):266–272. https://doi.org/10.1159/000085281 CrossRefPubMed

65.

Chen F-M, Ni J-M, Zhang Z-Y, et al. (2016) Presurgical evaluation of pancreatic cancer: a comprehensive imaging comparison of CT versus MRI. AJR Amer J Roentgenol 206(3):526–535. https://doi.org/10.2214/ajr.15.15236 CrossRef

66.

Joo I, Lee J, Lee D, et al. (2016) Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology 282(1):152798. https://doi.org/10.1148/radiol.2016152798

67.

Im HJ, Oo S, Jung W, et al. (2016) Prognostic value of metabolic and volumetric parameters of preoperative FDG-PET/CT in patients with resectable pancreatic cancer. Med (Baltimore) 95(19):e3686. https://doi.org/10.1097/MD.0000000000003686 CrossRef

68.

Lee J, Kang C, Choi H, et al. (2014) Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer. J Nucl Med 55(6):898–904. https://doi.org/10.2967/jnumed.113.131847 CrossRefPubMed

69.

Choi HJ, Lee JW, Kang B, et al. (2014) Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy. Yonsei Med J 55(6):1498–1506. https://doi.org/10.3349/ymj.2014.55.6.1498 CrossRefPubMedPubMedCentral

70.

Pimiento JM, Davis-Yadley AH, Kim RD, et al. (2016) Metabolic activity by 18F-FDG-PET/CT is prognostic for stage I and II pancreatic cancer. Clin Nucl Med 41(3):177–181. https://doi.org/10.1097/RLU.0000000000001098 CrossRefPubMedPubMedCentral

71.

Schellenberg D, Quon A, Minn AY, et al. (2010) 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 77(5):1420–1425. https://doi.org/10.1016/j.ijrobp.2009.06.049 CrossRefPubMed

72.

Moon SY, Joo KR, So YR, et al. (2013) Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer. Clin Nucl Med 38(10):778–783. https://doi.org/10.1097/RLU.0b013e31829f8c90 CrossRefPubMed

73.

Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B (2011) Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 11:123. https://doi.org/10.1186/1471-230X-11-123 CrossRefPubMedPubMedCentral

74.

Kuwatani M, Kawakami H, Eto K, et al. (2009) Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers. Intern Med 48(11):867–875CrossRefPubMed

75.

Sheikhbahaei S, Wray R, Young B, et al. (2016) 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction. Nucl Med Commun 37(3):231–238. https://doi.org/10.1097/MNM.0000000000000436 PubMed

76.

Nishiofuku H, Tanaka T, Marugami N, et al. (2015) Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Eur Radiol 26(6):1835–1842. https://doi.org/10.1007/s00330-015-3999-2 CrossRefPubMedPubMedCentral

Title: The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma
Authors: Randy Yeh
Laurent Dercle
Ishan Garg
Zhen Jane Wang
David M. Hough
Ajit H. Goenka
Publication date: 01-02-2018
Publisher: Springer US
Published in: Abdominal Radiology / Issue 2/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-017-1374-2

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Radiologic evaluation of patients undergoing the modified Appleby procedure for locally advanced pancreatic neoplasms: a case series

Rare pancreatic tumors

Pancreatic cancer screening

Multi-institutional survey on imaging practice patterns in pancreatic ductal adenocarcinoma

Imaging of post-operative pancreas and complications after pancreatic adenocarcinoma resection

Imaging findings of recurrent pancreatic cancer following resection

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage